Bluebird bio Inc (NASDAQ: BLUE) is -13.77% lower on its value in year-to-date trading and has touched a low of $0.88 and a high of $5.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BLUE stock was last observed hovering at around $1.26 in the last trading session, with the day’s loss setting it -0.07%.
Currently trading at $1.19, the stock is -9.40% and -5.06% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.68 million and changing -5.56% at the moment leaves the stock -54.22% off its SMA200. BLUE registered -59.52% loss for a year compared to 6-month loss of -58.82%. The firm has a 50-day simple moving average (SMA 50) of $16.51 and a 200-day simple moving average (SMA200) of -$2.72.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.39% gain in the last 1 month and extending the period to 3 months gives it a -13.14%, and is 0.85% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.13% over the week and 9.03% over the month.
Profit margin for the company is -419.62%. Distance from 52-week low is 35.38% and -78.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.06%).
Bluebird bio Inc quarterly earnings per share for the current quarter are estimated at -$0.64 with sales reaching $10.16M over the same period.The EPS is expected to grow by 10.88% this year, but quarterly earnings will post 881.40% year-over-year. Quarterly sales are estimated to grow 16,287.10% in year-over-year returns.
253 institutions hold shares in Bluebird bio Inc (BLUE), with institutional investors hold 70.88% of the company’s shares. The shares outstanding are 192.74M, and float is at 189.83M with Short Float at 15.67%. Institutions hold 70.61% of the Float.
The top institutional shareholder in the company is State Street Corporation with over 16.36 million shares valued at $53.82 million. The investor’s holdings represent 15.29% of the BLUE Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 8.79 million shares valued at $28.93 million to account for 8.22% of the shares outstanding. The other top investors are Tang Capital Management, LLC which holds 7.38 million shares representing 6.90% and valued at over $24.29 million, while Pfm Health Sciences, Lp holds 6.81% of the shares totaling 7.29 million with a market value of $23.97 million.
Bluebird bio Inc (BLUE) Insider Activity
The most recent transaction is an insider sale by Obenshain Andrew, the company’s President and CEO. SEC filings show that Obenshain Andrew sold 6,095 shares of the company’s common stock on Mar 04 ’24 at a price of $1.53 per share for a total of $9311.0. Following the sale, the insider now owns 0.28 million shares.
Bluebird bio Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Klima Thomas J () sold a total of 4,573 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $1.53 per share for $6986.0. Following the transaction, the insider now directly holds 0.12 million shares of the BLUE stock.
Still, SEC filings show that on Mar 01 ’24, Colvin Richard A (Chief Medical Officer) disposed off 6,770 shares at an average price of $1.53 for $10342.0. The insider now directly holds 118,368 shares of Bluebird bio Inc (BLUE).
